Bank Pictet & Cie Europe AG Invests $13.09 Million in Bristol-Myers Squibb (NYSE:BMY)

Bank Pictet & Cie Europe AG acquired a new position in shares of Bristol-Myers Squibb (NYSE:BMY) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 231,500 shares of the biopharmaceutical company’s stock, valued at approximately $13,094,000.

Several other institutional investors have also bought and sold shares of BMY. Valeo Financial Advisors LLC grew its position in Bristol-Myers Squibb by 8.4% in the fourth quarter. Valeo Financial Advisors LLC now owns 53,919 shares of the biopharmaceutical company’s stock valued at $3,050,000 after acquiring an additional 4,186 shares during the period. Roman Butler Fullerton & Co. grew its position in Bristol-Myers Squibb by 33.8% in the fourth quarter. Roman Butler Fullerton & Co. now owns 18,696 shares of the biopharmaceutical company’s stock valued at $1,133,000 after acquiring an additional 4,718 shares during the period. New York State Teachers Retirement System grew its position in Bristol-Myers Squibb by 0.7% in the fourth quarter. New York State Teachers Retirement System now owns 1,848,908 shares of the biopharmaceutical company’s stock valued at $104,574,000 after acquiring an additional 12,574 shares during the period. Campbell Wealth Management grew its position in Bristol-Myers Squibb by 217.9% in the fourth quarter. Campbell Wealth Management now owns 20,066 shares of the biopharmaceutical company’s stock valued at $1,135,000 after acquiring an additional 13,753 shares during the period. Finally, Asset Planning Inc bought a new stake in Bristol-Myers Squibb in the fourth quarter valued at $1,173,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Down 3.8 %

Shares of BMY opened at $53.85 on Friday. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.10. The firm has a market capitalization of $109.22 billion, a PE ratio of -12.18, a price-to-earnings-growth ratio of 2.13 and a beta of 0.45. The stock’s fifty day simple moving average is $57.32 and its 200-day simple moving average is $54.03.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.81% and a negative net margin of 18.53%. As a group, research analysts predict that Bristol-Myers Squibb will post 6.75 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd were paid a $0.62 dividend. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date was Friday, January 3rd. This represents a $2.48 annualized dividend and a yield of 4.61%. Bristol-Myers Squibb’s dividend payout ratio is presently -56.11%.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of analyst reports. BMO Capital Markets upped their price target on Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a research report on Tuesday, November 12th. Wells Fargo & Company boosted their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research note on Friday, February 7th. Leerink Partnrs raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 12th. Wolfe Research began coverage on Bristol-Myers Squibb in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. Finally, Jefferies Financial Group raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $63.00 to $70.00 in a research note on Monday, December 16th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, four have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $57.86.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.